FECM reported a total income of Rs 12.88 million, but faced an operating loss of Rs 0.86 million, indicating financial strain
Filed as: Financial Results for the Half Year Ended December 31, 2025
Summary
FECM reported a total income of Rs 12.88 million, but faced an operating loss of Rs 0.86 million, indicating financial strain.
Read the original filingFigures in the filing
| Item | This period | Period before | Change |
|---|---|---|---|
| Total Income | 12.88 | 11.99 | +7.4% |
| Total Expenses | 13.74 | 12.15 | +13.1% |
| Operating Loss | -0.86 | -0.16 | +437.5% |
| Profit After Taxation | -1.1 | -0.31 | +254.8% |
Amounts are in Pakistani rupees as stated in the filing (M = million, B = billion).
What the filing says
- Total income increased to Rs 12.88 million from Rs 11.99 million, reflecting a growth of 7.4%.
- Total expenses rose to Rs 13.74 million from Rs 12.15 million, leading to an operating loss of Rs 0.86 million.
- Profit after taxation declined to Rs -1.10 million compared to Rs -0.31 million in the prior period.
First Elite Capital Modaraba (FECM) on Nafa
Last price Rs 17.41 · Modarabas · You can own FECM shares from your phone.
More FECM announcements
- NoticeDissemination Of Video Recording Of Corporate Briefing Session
- NoticeTransmission of Quarterly Report for the Period Ended 30/09/2026
- NoticeGeneral Meetings / Briefing Sessions
- NoticeNotice of Corporate Briefing Session
- Financial resultFirst Elite Capital Modaraba reported a net loss of Rs 2.63 million for the quarter ended September 30, 2026Filed as: Financial Results for the Quarter Ended 30/09/2026
- NoticeBoard Meeting for the Quarter Ended 30-09-2026
Source: First Elite Capital Modaraba's filing with the Pakistan Stock Exchange. The summary and figures on this page are extracted from the filing by software and can contain errors; the filing itself is the record. This page describes the filing. It is not investment advice and Nafa does not recommend any stock. Investing in securities involves risk, including possible loss of principal.